7 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 recognized companies including Wyeth, Shire, and Sanofi, where he gained deep expertise in advancing innovative therapies and supporting organizational growth. Most notably, he joins Chrysalis not just as an industry veteran, but as a former client, having previously partnered with the company to launch and operate cleanroom-based manufacturing operations at Editas Medicine. “Adam’s deep operational and leadership experience is only strengthened by his unique understanding of our Chrysalis operating model,” said Sarah Stevens, CEO of Chrysalis. “He’s lived our customer experience first-hand, and brings a pragmatic, continuous improvement mindset that complements our ability to enable speed, quality, and flexibility for our customers.” As a former Senior Vice President of Business Operations at Editas Medicine, Bartley led programs through tech transfer and facility startup, while leveraging the Chrysalis’ cleanroom and support infrastructure. His experience as a customer will further strengthen our service delivery and growth. “As a client, I saw the value Chrysalis brings to growing biotechs – cutting out complexity and significant capital expenditure so teams can focus on science and execution,” said Bartley. “I’m excited to now be on the inside, helping scale that model and push operational boundaries to support even more clients.” Bartley’s appointment reflects Chrysalis’ continued investment in people and operational excellence as it expands its support of biopharma clients from development through GMP clinical and commercial production. Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. The JV will combine Quotient Sciences’ Translational Pharmaceutics® platform with CPI’s expertise in small scale manufacture of RNA and LNP encapsulation to deliver a firstof-its-kind, integrated offering for the development of mRNA drug products. The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence. “This is a pivotal moment for RNA drug development,” said Thierry Van Nieuwenhove, CEO at Quotient Sciences. “The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months. This offers a highly streamlined pathway to early-phase clinical trials for mRNA drug candidates”. The JV will integrate mRNA synthesis, LNP formulation development, clinical manufacturing, and early-phase clinical testing, all under one collaborative framework. The ability to quickly transition from DNA to RNA and into clinical trials will not only shorten timelines but also greatly increase the chances of clinical success, by affording drug developers the ability to adjust dose and formulation parameters based real-time clinical data from healthy human volunteers. This approach offers clear advantages in modalities where drug delivery is key to efficacy. Frank Millar, CEO at CPI, added: “We’re proud to be partnering with Quotient Sciences on this initiative which represents a bold step forward for the RNA ecosystem. Our shared vision is to enable scalable and sustainable development pathways for mRNA therapies that meet global health challenges head-on.” Translational Pharmaceutics® has been used globally by biotech and large pharma on over 500 programs with small molecule and peptide drug candidates. This JV extends the application of Translational Pharmaceutics into mRNA-based therapeutics. Details of the joint venture including name, branding, and operational roadmap will be announced as the collaboration progresses. Quotient Sciences and CPI to accelerate RNA drug development with joint venture NEWS
RkJQdWJsaXNoZXIy MjY2OTA4MA==